A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease

Inclusion Criteria:

- Has a diagnosis by the study investigator of a clinical syndrome of cognitive
impairment consistent with prodromal AD per International Working Group (IWG)
diagnostic criteria or mild cognitive impairment (MCI) due to AD per National
Institute on Aging-Alzheimer's Association (NIA-AA) diagnostic criteria.

- Scores 17-28 on Montreal Cognitive Assessment (MoCA) at screening.

- Scores <27 on free recall cutoff score from the Free and Cued Selective Reminding Test
(FCSRT) (Picture version) at screening.

- Scores ≤4 on Modified Hachinski Ischemia Scale (MHIS).

- Scores >0 on the Functional Activities Questionnaire (FAQ).

- Has a florbetapir positron emission tomography (PET) scan or cerebrospinal fluid (CSF)
result at screening consistent with the presence of amyloid pathology.

Exclusion Criteria:

- Has had MRI or computerized tomography (CT) of brain within previous 2 years showing
pathology that would be inconsistent with a diagnosis of AD.

- Has known allergy to humanized monoclonal antibodies.

- Has an ongoing clinically significant laboratory abnormality, as determined by the
investigator.

- Has screening MRI with results showing >4 amyloid related imaging abnormalities H
(ARIA-H) micro-hemorrhages or presence of ARIA-E.

- Has any contraindications for MRI studies, including claustrophobia, the presence of
metal (ferromagnetic) implants, or a cardiac pacemaker that is not compatible with
MRI.

- Has received treatment with a stable dose of an acetylcholinesterase (AChEI) inhibitor
or memantine for less than 2 months before randomization. (If a participant has
recently stopped AChEIs and/or memantine, he or she must have discontinued treatment
at least 2 months before randomization.)